Saturn V Capital Management LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Saturn V Capital Management LP reported 20 stock positions worth $544.9 million. Its top holding was Abivax SA-ADR (ABVX) at 16.1% of the portfolio, followed by Amylyx Pharmaceuticals (AMLX, 10.0%) and Cogent Biosciences (COGT, 7.9%). Compared with Q3 2025, it opened 8 new positions, sold out of 5, added to 4 and reduced 8. The biggest buy was a new position in Alumis (ALMS) and the biggest sale an exit from CG Oncology (CGON).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $544.9M (Q4 2025)
- SEC Filing
- 0001964437-26-000003 ↗ filed Feb 17, 2026
Holdings Value
Holdings 20 stocks · $544.9M
| ABVX Abivax SA-ADR | 16.07% | 649,179 | $87.5M | Reduce -19.0% |
| AMLX Amylyx Pharmaceuticals Inc. | 9.97% | 4,496,487 | $54.3M | Reduce -2.4% |
| COGT Cogent Biosciences Inc. | 7.93% | 1,217,064 | $43.2M | Reduce -39.9% |
| JAZZ Jazz Pharmaceuticals PLC | 7.74% | 248,070 | $42.2M | Reduce -17.5% |
| PCVX Vaxcyte Inc. | 6.77% | 798,940 | $36.9M | Add +1.3% |
| DYN Dyne Therapeutics Inc. | 6.42% | 1,788,616 | $35.0M | Reduce -33.1% |
| PHVS Pharvaris NV | 5.81% | 1,140,033 | $31.6M | Add +28.6% |
| CELC Celcuity Inc. | 5.80% | 317,095 | $31.6M | Reduce -33.1% |
| ALMS Alumis Inc. | 5.62% | 3,135,953 | $30.6M | New |
| IRON Disc Medicine Inc. | 4.35% | 298,429 | $23.7M | Reduce -12.5% |
| XFOR X4 Pharmaceuticals Inc. | 4.26% | 5,800,530 | $23.2M | New |
| MNPR Monopar Therapeutics Inc. | 3.90% | 325,701 | $21.3M | Add +109.6% |
| IVVD Invivyd Inc. | 3.51% | 7,735,386 | $19.1M | New |
| OCUL Ocular Therapeutix Inc. | 3.35% | 1,504,880 | $18.3M | Add +30.7% |
| IMMX Immix Biopharma Inc. | 2.88% | 2,999,169 | $15.7M | New |
| OCS Oculis Holding AG | 1.89% | 516,761 | $10.3M | New |
| IKT Inhibikase Therapeutics Inc. | 1.45% | 3,856,799 | $7.9M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 1.30% | 282,692 | $7.1M | Reduce -61.5% |
| OVID Ovid Therapeutics Inc. | 0.75% | 2,500,000 | $4.1M | New |
| IVA Inventiva SA - ADR | 0.24% | 283,166 | $1.3M | New |
Portfolio Sells Q3 2025 → Q4 2025
| CGON CG Oncology Inc. | Sold out | 0.00% | −5.12 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −4.44 |
| MRUS Merus NV | Sold out | 0.00% | −3.80 |
| LENZ Lenz Therapeutics Inc. | Sold out | 0.00% | −3.76 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -2.4% | 9.97% | −3.76 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -61.5% | 1.30% | −2.61 |
| DYN Dyne Therapeutics Inc. | Reduce -33.1% | 6.42% | −1.00 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −0.96 |
| JAZZ Jazz Pharmaceuticals PLC | Reduce -17.5% | 7.74% | −0.95 |
| IRON Disc Medicine Inc. | Reduce -12.5% | 4.35% | −0.59 |
| CELC Celcuity Inc. | Reduce -33.1% | 5.80% | +0.67 |
| ABVX Abivax SA-ADR | Reduce -19.0% | 16.07% | +1.15 |
| COGT Cogent Biosciences Inc. | Reduce -39.9% | 7.93% | +1.56 |
Portfolio Buys Q3 2025 → Q4 2025
| ALMS Alumis Inc. | New | 5.62% | +5.62 |
| XFOR X4 Pharmaceuticals Inc. | New | 4.26% | +4.26 |
| IVVD Invivyd Inc. | New | 3.51% | +3.51 |
| IMMX Immix Biopharma Inc. | New | 2.88% | +2.88 |
| OCS Oculis Holding AG | New | 1.89% | +1.89 |
| IKT Inhibikase Therapeutics Inc. | New | 1.45% | +1.45 |
| MNPR Monopar Therapeutics Inc. | Add +109.6% | 3.90% | +1.12 |
| PHVS Pharvaris NV | Add +28.6% | 5.81% | +0.96 |
| OVID Ovid Therapeutics Inc. | New | 0.75% | +0.75 |
| PCVX Vaxcyte Inc. | Add +1.3% | 6.77% | +0.54 |
| OCUL Ocular Therapeutix Inc. | Add +30.7% | 3.35% | +0.40 |
| IVA Inventiva SA - ADR | New | 0.24% | +0.24 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |